How Much Lower Can Shire PLC Go?

Shire PLC (LON: SHP) and AstraZeneca plc (LON:AZN) could fall further now mergers are off the table.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shire’s (LSE: SHP) shares are falling once again today, after AbbVie announced that its board of directors was recommending company’s shareholders vote against the takeover of Shire. shire

This news comes after AbbVie’s announcement yesterday that the company was reconsidering its offer to acquire Shire, after taking into account the US Treasury’s new rules on tax inversion deals. So, now that AbbVie’s management has withdrawn its recommendation to vote for the merger, it looks as if the deal is off the table.

Shire’s management has issued a press release this morning stating that it is assessing the current situation and a further announcement will be made in due course.

Further to fall

Following these developments, it’s likely that the valuations of both Shire and its larger peer, AstraZeneca (LSE: AZN), could fall as the two groups are no longer attractive takeover targets. 

Indeed, Astra’s shares have been held above the key 4,000p level for much of this year as investors speculate that global pharmaceutical giant Pfizer will come back and make a new, higher offer for the company.

But now, with the possibility of a new offer fading, Astra’s shares look overpriced. For example, Astra currently trades at a forward P/E of 15.9, compared to the pharmaceutical & biotech average sector P/E of 13.1. As the prospects of a bid disappear, Astra’s shares could fall by around 17% to 3,524p, which would bring them into line with the sector’s average valuation.  

In addition, now AbbVie is no longer courting Shire, Shire’s shares could also fall to a valuation that’s more in line with the rest of the sector. Unfortunately, Shire is currently trading at one of the highest valuations in the pharmaceutical & biotech sector — the company trades at a forward P/E of 20.3 — so the group could see its share price fall as low as 2,500p now a deal is off the table. 

Bright prospects

Still, while Shire and Astra might see their share prices fall in the short-term, over the longer term the two companies have a bright future.

For example, Shire should receive a break-up fee of around $1.6bn from AbbVie if the takeover collapses, which will give the company a large acquisition war chest. Shire has built itself up to where it is today by acquiring smaller competitors with outstanding products, further deals could now be on the cards.

Meanwhile, Astra is priming itself for growth and is currently developing several cancer treatments. These treatments have been touted as game-chaining products for the pharmaceutical industry and management believes that these products will help the company double sales by 2023. 

Long-term plays

Overall, even though Shire and Astra are no longer acquisition targets, they remain great long-term investments due to their defensive nature and plans for growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »